News & Publications

Check out the latest news and publications.

In The News

Neuroscience Working Table Supports Neurology Drug Program Funding in FY 23′ Agriculture-FDA Appropriation Bill
September 7, 2022

The undersigned members of the brain health community write to express our gratitude for the inclusion of $3 million in funding and accompanying report language in support of the Neurology Drug Program at the Food and Drug Administration (FDA) in the Senate Committee’s draft fiscal year (FY) 23 Agriculture, Rural Development, FDA, and Related Agencies […]

Read More >
Fiscal Year 2023 Senate Agriculture, Rural Development, FDA, and Related Agencies Appropriations Bill
July 28, 2022

The Senate Appropriations Committee included funding for FDA’s Neurology Drug Program in its FY 2023 funding bill. Here is the language from its Explanatory Statement: “The Committee provides $3,000,000 to support and enhance the neurology drug program. Unprecedented progress in understanding the cellular and molecular processes that underlie human nervous systems holds the promise of […]

Read More >
Understanding the Need for a Neuroscience Center of Excellence at the FDA
March 25, 2022

Understanding the Need for a Neuroscience Center of Excellence at the FDA Central Nervous System (CNS) Diseases Afflict Millions and Cost Billions Each Year As of 2020, nearly 100 million Americans suffered from psychiatric and neurological diseases, costing $760 billion annually.[i] The Centers for Disease Control and Prevention (CDC) forecasts that the number of Americans […]

Read More >
Neuroscience Working Table Statement for the Record: House E&C March 17 User Fee Hearing
March 23, 2022

The Neuroscience Working Table (“Working Table”), which includes more than 40 organizations and coalitions representing more than 100 million Americans with psychiatric and neurologic diseases, writes to commend you for holding this important legislative hearing. One of the bills under consideration, H.R. 6000, would require the establishment of additional centers of excellence at the Food […]

Read More >
Report: Incentivizing Drug Development for Serious Mental Illness
March 23, 2022

The Tufts Center for the Evaluation of Value and Risk in Health has released a report entitled “Incentivizing Drug Development for Serious Mental Illness.” The report examines unmet medical need in this area, exploring why bio-pharmaceutical innovation for serious mental illness has lagged behind other therapeutic areas.  It provides an overview of barriers to innovation […]

Read More >
Blog Post: Institute for Patient Access Advocating for NCOE
March 21, 2022

On March 15, the Institute for Patient Access published a blog post that advocates for the the creation of a Neuroscience Center of Excellence. The post notes that “[b]ipartisan congressional efforts are underway that would pave the way for a Neuroscience Center of Excellence to accelerate the prevention, treatment and curing of neurological diseases. Legislation […]

Read More >
State Profiles of CNS Disease Burden
March 14, 2022

Approximately 100 million Americans suffer from at least one of the more than 1,000 neurological diseases that are known to exist. With such high prevalence across the country, individuals suffering from neurological diseases and disorders can be found in every state.  Click on individual states to access a state profile document, which offers an illustrative […]

Read More >
Study: The Need for New Approaches in CNS Drug Discovery: Why Drugs Have Failed, and What Can Be Done to Improve Outcomes
March 9, 2022

An important goal of biomedical research is to translate basic research findings into useful medical advances. In the field of neuropharmacology this requires understanding disease mechanisms as well as the effects of drugs and other compounds on neuronal function. Our hope is that this information will result in new or improved treatment for CNS disease. […]

Read More >
Neuroscience Working Table Letter of Support for S. 3427
February 15, 2022

The Neuroscience Working Table (“Working Table”), which includes organizations and coalitions representing more than 100 million Americans with psychiatric and neurologic diseases, writes to express our support for S. 3427, “the Neuroscience Center of Excellence Act of 2021” introduced on December 16, 2021. We commend your leadership in authoring a bill that would require the […]

Read More >
Interview with Two Working Table Members on the Need for a Center and How it Would Help
January 24, 2022

Brain research is one of the most complex and challenging areas of scientific investigation, and the field of neuroscience drug development is crowded with failed clinical trials. In fact, treatments for central nervous system (CNS) disorders fail at higher rates than drugs in other areas and they take longer to win approval than non-CNS drugs, […]

Read More >
Neuroscience Working Table Statement of Support
January 12, 2022

“The Neuroscience Working Table (“Working Table”), which includes organizations and coalitions representing more than 100 million Americans with psychiatric and neurologic diseases, commends Senator Collins (R-ME) and Senator Luján (D-NM) for introducing S. 3427, “the Neuroscience Center of Excellence Act of 2021”. The bill would require the establishment of a Neuroscience Center of Excellence at […]

Read More >
Neuroscience Working Table Letter of Support for HR 6000 Cures 2.0
December 13, 2021

Dear Representatives DeGette and Upton: The Neuroscience Working Table (“Working Table”), which includes organizations and coalitions representing more than 100 million Americans with psychiatric and neurologic diseases, writes to express our support for Section 306 included in H.R. 6000, “the Cures 2.0 Act” introduced on November 17, 2021. This Section would require the establishment of […]

Read More >
Energy and Commerce Statement for Record
July 29, 2021

Dear Chair Eshoo and Ranking Member Guthrie, The Neuroscience Working Table (“Working Table”), which includes organizations and coalitions representing more than 50 million Americans with psychiatric and neurologic diseases, writes to commend you for holding this important hearing on the challenges and opportunities in neurological research as you consider ways federal policy can help respond […]

Read More >
Neuroscience Working Table Cures 2.0 Discussion Letter
July 16, 2021

Dear Representatives DeGette and Upton: The Neuroscience Working Table (“Working Table”), which includes organizations and coalitions representing more than 50 million Americans with psychiatric and neurologic diseases, writes to express our support for Section 306 included in the “Cures 2.0 Act” released on June 22, 2021. This Section would require the establishment of additional centers […]

Read More >
Understanding the Need for a Neuroscience Center of Excellence at the FDA
July 15, 2021

Central Nervous System (CNS) Diseases Afflict Millions and Cost Billions Each Year As of 2020, nearly 100 million Americans suffered from psychiatric and neurological diseases, costing $760 billion annually. The Centers for Disease Control and Prevention (CDC) forecasts that the number of Americans with some form of dementia will double by 2060 to 13.9 million […]

Read More >
Understanding FDA’s Oncology Center of Excellence
July 15, 2021

The Food and Drug Administration’s (FDA’s) Oncology Center of Excellence (OCE) leverages the combined skills of regulatory scientists and reviewers with expertise in drugs, biologics, devices, and diagnostics. The Center helps expedite development of medical products for oncologic and hematologic malignancies and supports an integrated approach to their clinical evaluation by working with centers and […]

Read More >